Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line
- 1 November 1996
- journal article
- research article
- Published by Taylor & Francis in Endocrine Research
- Vol. 22 (4) , 709-715
- https://doi.org/10.1080/07435809609043766
Abstract
We investigated the effects of taxol, an antimicrotubule agent active in different cancers, on the human NCI-H295 steroid-secreting adrenocortical carcinoma cell line. Cells were incubated for 48, 72 or 96 h with taxol 10-10-10-4 M. Cell viability was evaluated by MTT assay with IC50 calculation. Apoptosis was investigated by measuring DNA fragmentation with ELISA assay after cell exposure to taxol at IC50 for 24 h. For secretion studies, aldosterone, cortisol, testosterone and dehydroepiandrosterone-sulphate (DHEA-S) were measured by RIA in the conditioned medium after 96 h exposure to taxol 10-10-10-6 M, and expressed as percentage of steroid production by control cells. By MTT, taxol induced a dose-dependent inhibition of cell proliferation, with ICs50 at 72–96 h corresponding to blood levels achieved in vivo in patients with other types of cancer. Nuclear fragmentation, morphologically confirmed at electron microscopy, showed a 4-fold increase after exposure to taxol. With 10-6 M taxol, aldosterone decreased to 48%, cortisol to 61%, testosterone to 76% and DHEA-S to 89% of steroid production by control cells. Taxol is an effective cytotoxic and antiproliferative agent in a human adrenocortical steroid-secreting carcinoma cell line. Apoptosis induced by the drug is involved in neoplastic cell death.Keywords
This publication has 10 references indexed in Scilit:
- Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosisNature Medicine, 1996
- Mechanisms of Apoptosis: Integration of Genetic, Biochemical, and Cellular IndicatorsJNCI Journal of the National Cancer Institute, 1994
- Paclitaxel (Taxol): A Novel Anticancer Chemotherapeutic DrugMayo Clinic Proceedings, 1994
- Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinomaCancer Chemotherapy and Pharmacology, 1993
- Treating Adrenal CancerThe Endocrinologist, 1992
- Synthesis of 19-nor-aldosterone, 18-hydroxy-19-nor-corticosterone and 18,19-dihydroxycorticosterone in the human aldosterone-producing adenomaThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- Suramin in Adrenal Cancer: Modulation of Steroid Hormone Production, Cytotoxicityin Vitro, and Clinical Antitumor Effect*Journal of Clinical Endocrinology & Metabolism, 1990
- Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane TherapyNew England Journal of Medicine, 1990
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983
- Cell Death: The Significance of ApoptosisPublished by Elsevier ,1980